Follow-Up Study in Lymph Node-Negative Penile Cancer Suggests Reduced Check-Ups After First Year

What is it about?

The study evaluates the follow-up (FU) schedule for patients with lymph node-negative penile squamous cell carcinoma (PSCC), particularly focusing on the use of ultrasonography (US) and US-guided fine-needle aspiration cytology (FNAC). Conducted at a high-volume center, the study analyzed 201 patients with PSCC, performing 2694 US procedures and 270 FNACs. The results revealed a low incidence of lymph node metastasis, with only four detected cases, indicating that routine US at every visit is excessive. The study suggests that patients with clinically node-negative (cN0) and sentinel node-negative (pN0) PSCC rarely develop lymph node metastasis during follow-up, recommending that US should be conducted quarterly only in the first year post-treatment. This approach could reduce follow-up visits by up to 50% compared to current guidelines, benefiting patients capable of self-examination.

Featured Image

Why is it important?

This research is important because it evaluates the follow-up schedule for patients with lymph node-negative penile squamous cell carcinoma (PSCC) and offers insights into optimizing the surveillance strategy. By assessing the effectiveness of routine ultrasonography (US) and US-guided fine-needle aspiration cytology (FNAC), the study contributes to understanding how to balance effective cancer monitoring with the reduction of unnecessary medical procedures and visits. It highlights the potential for reducing medical costs and patient burden while maintaining adequate cancer surveillance, thus improving patient quality of life and healthcare efficiency. Key Takeaways: 1. Low Recurrence Rate: The study found that patients with cN0/pN0 PSCC rarely develop lymph node metastasis during follow-up, with only 0.2% of US procedures detecting recurrence, indicating the low necessity for frequent imaging. 2. Follow-Up Optimization: The results suggest that routine US should be limited to the first year after treatment when metastasis is most likely, and further follow-up can be reduced, especially for patients capable of self-examination. 3. Guideline Implications: By proposing a reduction in follow-up visits and imaging after the first year, the study challenges current guidelines, advocating for a more tailored approach that could lead to significant reductions in follow-up appointments, potentially cutting them by up to 50%.